Diphtheria - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H2 2016, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 1, 5, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.Diphtheria.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Diphtheria Overview 9
Therapeutics Development 10
Pipeline Products for Diphtheria - Overview 10
Pipeline Products for Diphtheria - Comparative Analysis 11
Diphtheria - Therapeutics under Development by Companies 12
Diphtheria - Therapeutics under Investigation by Universities/Institutes 14
Diphtheria - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diphtheria - Products under Development by Companies 18
Diphtheria - Products under Investigation by Universities/Institutes 20
Diphtheria - Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
BioClonetics Immunotherapeutics, Inc. 22
Biological E. Limited 23
Boryung Pharmaceutical Co., Ltd. 24
Daiichi Sankyo Company, Limited 25
GlaxoSmithKline Plc 26
Green Cross Corporation 27
Indian Immunologicals Limited 28
Kaketsuken K.K. 29
LG Life Science LTD. 30
Panacea Biotec Limited 31
Prometheon Pharma, LLC 32
Sanofi Pasteur SA 33
Serum Institute of India Pvt Ltd 34
Sinovac Biotech Ltd. 35
Zydus Cadila Healthcare Limited 36
Diphtheria - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
(diphtheria + tetanus) vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
BVN-002 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
diphtheria vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Eupenta - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
GC-1107 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
GC-3111A - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
KD-370 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
LBVD - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Monoclonal Antibody for Diphtheria - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
VN-0103 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
VN-0105 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Diphtheria - Dormant Projects 78
Diphtheria - Discontinued Products 79
Diphtheria - Product Development Milestones 80
Featured News & Press Releases 80
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 80
Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA 80

Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 82

List of Tables

Number of Products under Development for Diphtheria, H2 2016 10
Number of Products under Development for Diphtheria - Comparative Analysis, H2 2016 11
Number of Products under Investigation by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 21
Diphtheria - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 22
Diphtheria - Pipeline by Biological E. Limited, H2 2016 23
Diphtheria - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016 24
Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 25
Diphtheria - Pipeline by GlaxoSmithKline Plc, H2 2016 26
Diphtheria - Pipeline by Green Cross Corporation, H2 2016 27
Diphtheria - Pipeline by Indian Immunologicals Limited, H2 2016 28
Diphtheria - Pipeline by Kaketsuken K.K., H2 2016 29
Diphtheria - Pipeline by LG Life Science LTD., H2 2016 30
Diphtheria - Pipeline by Panacea Biotec Limited, H2 2016 31
Diphtheria - Pipeline by Prometheon Pharma, LLC, H2 2016 32
Diphtheria - Pipeline by Sanofi Pasteur SA, H2 2016 33
Diphtheria - Pipeline by Serum Institute of India Pvt Ltd, H2 2016 34
Diphtheria - Pipeline by Sinovac Biotech Ltd., H2 2016 35
Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 36
Assessment by Monotherapy Products, H2 2016 37
Assessment by Combination Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Route of Administration, H2 2016 42
Number of Products by Stage and Molecule Type, H2 2016 44
Diphtheria - Dormant Projects, H2 2016 78
Diphtheria - Discontinued Products, H2 2016 79